Immunotherapy for HCV infection: Next steps

Expert Review of Vaccines

Volumn 7, Issue 7, 2008, Pages 915-923

  Lang, Krystle ^a   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

HCV; Immunotherapy; Interferon; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON A; CHRONVAC C; CONSENSUS INTERFERON; CPG 10101; DNA VACCINE; HEPATITIS C VACCINE; IC 41; INNOVAC C; ISATORIBINE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; RECOMBINANT GPE1; RECOMBINANT GPE2; RIBAVIRIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 AGONIST; UNCLASSIFIED DRUG; VIRUS RNA;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMPANZEE; CHRONIC HEPATITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG COST; DRUG MEGADOSE; DRUG TOLERABILITY; ECONOMIC ASPECT; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PANDEMIC; PERSISTENT INFECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

HEPATITIS C; HUMANS; IMMUNOTHERAPY; INTERFERONS; TOLL-LIKE RECEPTORS; UNITED STATES; VIRAL HEPATITIS VACCINES;

EID: 51549108762     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.7.915     Document Type: Review

References (76)

1. Thomson BJ, Finch RG. Hepatitis C virus infection. Clin. Microbiol. Infect. 11(2), 86-94 (2005).
2. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon α. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 321(22), 1501-1506 (1989).
3. McHutchison JG, Gordon SC, Schiff ER et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339(21), 1485-1492 (1998).
4. Poynard T, Vernisse B, Agostini H. Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux. Aliment Pharmacol. Ther. 12(2), 159-165 (1998).
5. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment - finding the right path. Nat. Rev. Drug Discov. 6(12), 991-1000 (2007). • Excellent review on other therapies currently in development for the treatment of HCV infection besides immunotherapies.
6. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436(7053), 946-952 (2005). • Excellent review on the correlates of immune protection for HCV infection.
7. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 436(7053), 961-966 (2005).
8. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55(9), 1350-1359 (2006).
9. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358(9286), 958-965 (2001).
10. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975-982 (2002).
11. Balan V, Nelson DR, Sulkowski MS et al. A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-α fusion protein in chronic hepatitis C patients who have failed previous interferon-α-based therapy. Antivir. Ther. 11(1), 35-45 (2006).
12. Bain VG, Kaita KD, Yoshida EM et al. A Phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon α fusion protein in genotype 1 chronic hepatitis C patients. J. Hepatol. 44(4), 671-678 (2006).
13. Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-α species, consensus interferon. J. Interferon Cytokine Res. 16(7), 489-499 (1996).
14. Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW. A comparison of interferon-Con1 with natural recombinant interferons-α: antiviral, antiproliferative, and natural killer-inducing activities. J. Interferon Res. 12(1), 55-59 (1992).
15. Sjogren MH, Sjogren R, Holtzmuller K et al. Interferon acon-1 and ribavirin versus interferon α-2b and ribavirin in the treatment of chronic hepatitis C. Dig. Dis. Sci. 50(4), 727-732 (2005).
16. Fattovich G, Zagni I, Minola E et al. A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. J. Hepatol. 39(5), 843-849 (2003).
17. Tong MJ, Reddy KR, Lee WM et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 26(3), 747-754 (1997).
18. Barbaro G, Barbarini G. Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon α-2b and ribavirin in combination: an Italian pilot study. Eur. J. Gastroenterol. Hepatol. 14(5), 477-483 (2002).
19. Shiffman ML, Di Bisceglie AM, Lindsay KL et al. Peginterferon α-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126(4), 1015-1023; discussion 1947 (2004).
20. Jacobson IM, Gonzalez SA, Ahmed F et al. A randomized trial of pegylated interferon α-2b plus ribavirin in the retreatment of chronic hepatitis C. Am. J. Gastroenterol. 100(11), 2453-2462 (2005).
21. Cornberg M, Hadem J, Herrmann E et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J. Hepatol. 44(2), 291-301 (2006).
22. McHutchison JG, Bacon BR, Gordon SC et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 46(5), 1341-1349 (2007).
23. Horsmans Y, Berg T, Desager JP et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 42(3), 724-731 (2005).
24. Weiner AJ, Paliard X, Selby MJ et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J. Virol. 75(15), 7142-7148 (2001).
25. Bassett SE, Guerra B, Brasky K et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 33(6), 1479-1487 (2001).
26. Lanford RE, Guerra B, Chavez D et al. Cross-genotype immunity to hepatitis C virus. J. Virol. 78(3), 1575-1581 (2004).
27. Pawlotsky JM. Diagnostic tests for hepatitis C. J. Hepatol. 31(Suppl. 1), 71-79 (1999).
28. Farci P, Alter HJ, Govindarajan S et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 258(5079), 135-140 (1992).
29. Lai ME, Mazzoleni AP, Argiolu F et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 343(8894), 388-390 (1994).
30. Cooper S, Erickson AL, Adams EJ et al. Analysis of a successful immune response against hepatitis C virus. Immunity 10(4), 439-449 (1999).
31. Post JJ, Pan Y, Freeman AJ et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J. Infect. Dis. 189(10), 1846-1855 (2004).
32. Qureshi SA. Hepatitis C virus - biology, host evasion strategies, and promising new therapies on the horizon. Med. Res. Rev. 27(3), 353-373 (2007).
33. Rispeter K, Lu M, Behrens SE, Fumiko C, Yoshida T, Roggendorf M. Hepatitis C virus variability: sequence ana lysis of an isolate after 10 years of chronic infection. Virus Genes 21(3), 179-188 (2000).
34. Lechner F, Wong DK, Dunbar PR et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191(9), 1499-1512 (2000).
35. + T-cell response in acute hepatitis C. Gastroenterology 117(4), 933-941 (1999).
36. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194(10), 1395-1406 (2001).
37. Grakoui A, Shoukry NH, Woollard DJ et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302(5645), 659-662 (2003).
38. + T cells in clearance of HCV infection.
39. Rehermann B, Chang KM, McHutchison JG, Kokka R, Houghton M, Chisari FV. Quantitative ana lysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J. Clin. Invest. 98(6), 1432-1440 (1996).
40. Lechner F, Wong DK, Dunbar PR et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 1499-1512 (2000).
41. Lauer GM, Barnes E, Lucas M et al. High resolution ana lysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127(3), 924-936 (2004).
42. Frese M, Schwarzle V, Barth K et al. Interferon-g inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 35(3), 694-703 (2002).
43. Missale G, Bertoni R, Lamonaca V et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 98(3), 706-714 (1996).
44. Diepolder HM, Zachoval R, Hoffmann RM et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346(8981), 1006-1007 (1995).
45. + T-helper-cell responses in resolved hepatitis C virus infection. J. Virol. 76(24), 12584-12595 (2002).
46. Choo QL, Kuo G, Ralston R et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl Acad. Sci. USA 91(4), 1294-1298 (1994).
47. Youn JW, Park SH, Lavillette D et al. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology 42(6), 1429-1436 (2005).
48. Elmowalid GA, Qiao M, Jeong SH et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc. Natl Acad. Sci. USA 104(20), 8427-8432 (2007).
49. Folgori A, Capone S, Ruggeri L et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 12(2), 190-197 (2006). • Important paper showing that vaccine-induced cellular immune responses could be protective in heterologous HCV challenge in chimpanzees.
50. Rollier C, Depla E, Drexhage JA et al. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J. Virol. 78(1), 187-196 (2004).
51. Capone S, Meola A, Ercole BB et al. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-Ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J. Virol. 80(4), 1688-1699 (2006).
52. Capone S, Zampaglione I, Vitelli A et al. Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J. Immunol. 177(10), 7462-7471 (2006).
53. Nelson DR, Marousis CG, Davis GL et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J. Immunol. 158(3), 1473-1481 (1997).
54. + T cells in chronic hepatitis C virus infection. J. Immunol. 169(6), 3447-3458 (2002).
55. + T lymphocytes after infection with hepatitis C virus. J. Virol. 75(12), 5550-5558 (2001).
56. + lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J. Virol. 76(24), 12423-12434 (2002).
57. + T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8(4), 379-385 (2002).
58. + T cells by flow cytometry: correlation with clinical disease stages. Hepatology 35(1), 190-198 (2002).
59. Nevens F, Roskams T, Van Vlierberghe H et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38(5), 1289-1296 (2003).
60. Leroux-Roels G, Depla E, Hulstaert F et al. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 22(23-24), 3080-3086 (2004).
61. + T cells in healthy individuals and chronic hepatitis C patients. Vaccine 25(37-38), 6793-6806 (2007).
62. Firbas C, Jilma B, Tauber E et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 24(20), 4343-4353 (2006).
63. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther. 6(4), 508-514 (1999).
64. Gronevik E, von Steyern FV, Kalhovde JM, Tjelle TE, Mathiesen I. Gene expression and immune response kinetics using electroporation-mediated DNA delivery to muscle. J. Gene Med. 7(2), 218-227 (2005).
65. Peng B, Zhao Y, Xu L, Xu Y. Electric pulses applied prior to intramuscular DNA vaccination greatly improve the vaccine immunogenicity. Vaccine 25(11), 2064-2073 (2007).
66. + T cells. J. Immunol. 179(7), 4741-4753 (2007).
67. Liu J, Kjeken R, Mathiesen I, Barouch DH. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J. Virol. 82(11), 5643-5649 (2008).
68. Puig M, Major ME, Mihalik K, Feinstone SM. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 22(8), 991-1000 (2004).
69. Rollier CS, Paranhos-Baccala G, Verschoor EJ et al. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 45(3), 602-613 (2007).
70. Hepatitis C www.who.int/csr/disease/hepatitis/HepC.pdf
71. Hepatitis C: CDC viral hepatitis www.cdc.gov/NCIDOD/diseases/hepatitis/c/ faq.htm#1a
72. DIRECT trial www.directtrial.com/sec/design.html
73. World Health Organisation: hepatitis C www.who.int/mediacentre/ factsheets/fs164/en/
74. Drug Information Online www.drugs.com/clinical_trials/intercell-8217-s- therapeutic-hepatitis-c-vaccinemeets-primary-endpoints-phase-ii-3345.html
75. CHRONVAC-C® study http://clinicaltrials.gov/ct2/show/NCT00563173
76. Safety results of Tripep's ChronVac-C delivered using Inovio's electroporation delivery systems www.tradingmarkets.com/.site/news/ breaking%20news/1209773/?hcode=relatednews